



Grants Issued For Very Early Cancer Detection & Treatment

November 9, 2010

ALBUQUERQUE, N.M.--Manhattan Scientifics, Inc. (OTCBB: MHTX) announced that Senior Scientific LLC is the recipient of four grants totaling \$702,899 awarded by the Qualifying Therapeutic Discovery Grant Program. The grants are funded by the US government to develop new therapies, reduce long-term health care costs, and advance the goal of curing cancer; exact use of proceeds will be determined by Senior Scientific. Manhattan Scientifics has the exclusive rights to commercialize Senior Scientific's Cancer Detection and Treatment technology, improving health care while reducing the cost of medical treatment.

These awards substantiate the unique programs of Senior Scientific to use advances in nanotechnology and nanomedicine to detect and treat disease at an early stage. The four grants received are for different applications of this new nanotechnology developed by Senior Scientific. All of these programs have been funded by Phase II Small Business Innovative Research grants from the NIH.

The NIH awards and the new QTDP grants cover four projects: (1) development of a new sensitive method for detecting early stages of breast cancer and monitoring therapy; (2) detection of ovarian cancer before symptoms appear that indicate the cancer has already spread; (3) detection of minimal residual disease in leukemia patients undergoing treatment with the goal of minimizing chemotherapy; and (4) development of a non-invasive method to determine if a transplanted organ is being rejected (without the need for a biopsy), and to determine if anti-rejection therapy is required.

About Manhattan Scientifics

Manhattan Scientifics, Inc., (OTCBB: MHTX), is a leading information age enterprise focused on the nanomedicine space. Located in New Mexico, New York and Montreal, Manhattan Scientifics' goal is to create profit for the company's shareholders through royalty-bearing licenses with Fortune 1000 companies by marketing products that rely on the company's patents, know-how and intellectual property. Manhattan Scientifics owns the exclusive, perpetual U.S. license to a family of patents which will enable the manufacture and marketing of super strong, ultra light-weight "nanostructured" metals that have been developed at the Los Alamos National Laboratory (LANL) and in the former Soviet Union. More information about Manhattan Scientifics can be found at www.mhtx.com and at www.seniorscientific.com

Forward-looking statement

This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.

Contacts

Manhattan Scientifics, Inc.

Marvin Maslow, Director of PR & IR, 917-923-3300

Email: marvin@mhtx.com



U.S. & Canadian Investor Relations

Hawk Associates: Frank Hawkins, 305-451-1888

Email: f.hawkins@hawkassociates.com